Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia
Open Access
- 14 October 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 4842-4847
Abstract
Venetoclax is highly active in previously treated Waldenström macroglobulinemia (WM). However, data on the long-term durability and retreatment with venetoclax remain limited. Herein, we present an update of a prospective clinical trial of finite-duration venetoclax on 32 previously treated patients with WM. With a median follow-up of 81 months, 23 patients (72%) had disease progression, 17 (53%) began a new treatment, and 3 (9%) had died. The median progression-free survival (PFS) was 36 months, and the median treatment-free survival (TFS) was 43 months. PFS and TFS were superior in patients who attained at least a partial response to therapy. CXCR4 mutations or previous Bruton tyrosine kinase inhibitor exposure did not impact these outcomes. Of the 17 patients who started a new therapy after completion of venetoclax therapy, 9 were retreated with venetoclax alone or in combination with other treatments (3 attained a very good partial response, 4 attained a partial response, 1 had stable disease, and 1 did not respond). No BCL2 G101V mutations were detected in 52 CD19-selected bone marrow samples from 27 patients during treatment. Venetoclax induced durable responses in WM, thereby enabling retreatment in patients who progressed after completing therapy without the emergence of BCL2 G101V mutations. This trial was registered at www.ClinicalTrials.gov as #NCT02677324.Keywords
This publication has 22 references indexed in Scilit:
- Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysisBlood Cancer Journal, 2025
- Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN StudyBlood, 2022
- Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström MacroglobulinemiaHemaSphere, 2021
- Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based RegimenBlood, 2020
- Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundAmerican Journal of Hematology, 2018
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyThe Lancet Oncology, 2017
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaNew England Journal of Medicine, 2015
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopBritish Journal of Haematology, 2012
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003